Patent Highlight: How Might Puhe BioPharma’s WRN Helicase Inhibitors Differentiate from Novartis’?
Other articles you may be interested in
Drug Hunter Annotated Patent Database Search
As part of our series of monthly patent roundup articles, which bring you highlights of the most relevant drug discovery IP disclosures, by member request we have collated recent selections into a single searchable table. This tool allows you to see longer-term industry trends in therapeutic areas and target selection to inspire ideas for your pipeline.
Patent Highlight: Highly Selective TREX1 Inhibitors from Constellation Pharmaceuticals
This article highlights a patent application from Constellation Pharmaceuticals that discloses the biological activity of compounds that act as TREX1 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.
August 2024 Annotated Searchable Patent Table
We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published patent documents to bring you a curated list of over 200 key patents released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently.
June 2024 Patent Highlights: GLP-1R Agonists, Polθ Inhibitors, Non-Ab PD-L1 Inhibitors, and More!
To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in June 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as synthetically lethal Polθ inhibitors, SARM1 inhibitors for neurodegenerative indications, and our best guess at the identity of Gilead’s small molecule GLP-1R agonist GS-4571
Patent Highlights: pan-KRAS Inhibitors, Tumor Cell-Activated KARS (not KRAS) Inhibitors, MK2 Degraders, IL-17A Inhibitors, and More!
This article highlights the key drug discovery patents published in August 2024, including AKR1C3-dependent KARS (not KRAS!) inhibitors for NRF2/KEAP1-mutated cancers and DHX9 helicase inhibitors of MSI-high tumors. It also covers the development of MK2 degraders for inflammatory diseases and small molecule IL-17A inhibitors that show promise in modulating inflammation. Additionally, we cover Roche’s take on Revolution Medicines’ macrocyclic pan-KRAS inhibitors, which show improved PK profiles, and novel non-hydroxamate LpxC inhibitors for treating Gram-negative bacterial infections.
